# Insurance Appeals Service

**Document Version**: 1.0
**Last Updated**: November 8, 2025
**Owner**: Chief Patient Services Officer
**Purpose**: Comprehensive service to help AATD patients fight insurance denials and obtain coverage for medically necessary testing, treatment, and care

---

## üìã Table of Contents

1. [Service Overview](#service-overview)
2. [Why This Service Matters](#why-this-service-matters)
3. [Common Insurance Denials](#common-insurance-denials)
4. [Service Components](#service-components)
5. [Appeals Process](#appeals-process)
6. [Resources & Templates](#resources-templates)
7. [Volunteer Network](#volunteer-network)
8. [Success Metrics](#success-metrics)

---

## Service Overview

### What We Offer

**Mark Egly Foundation Insurance Appeals Service** provides **FREE support** to AATD patients fighting insurance denials:

**Services Include**:

- ‚úÖ **Appeals Consultation**: Expert guidance on fighting insurance denials
- ‚úÖ **Template Letters**: Pre-written appeal letters (customizable)
- ‚úÖ **Medical Evidence Package**: Research, clinical guidelines, expert opinions
- ‚úÖ **Expert Witness Coordination**: Connect patients with physicians who'll write support letters
- ‚úÖ **Peer Review Challenges**: Request independent medical review
- ‚úÖ **External Appeals Support**: File external appeals (state insurance commissioner, independent review)
- ‚úÖ **Attorney Referrals**: Connect to pro bono attorneys (for denied appeals)

**Who Can Use**:

- Any AATD patient (diagnosed or suspected)
- Family members (parents of pediatric patients)
- Healthcare providers (on behalf of patients)
- **No cost** to patients (100% donor-funded)

---

### Service Goals

**Year 1** (2026):

- Assist 100 patients with insurance appeals
- 75% success rate (denials overturned)
- Build template library (10+ appeal letter templates)
- Recruit 20 volunteer attorneys + 10 physician expert witnesses

**Year 3** (2028):

- Assist 500 patients/year
- 80% success rate
- Expand to class action suits (systemic denial patterns)

**Year 5** (2030):

- Assist 1,000 patients/year
- 85% success rate
- Policy change (reduce prior authorization barriers)

---

## Why This Service Matters

### Insurance Denials = #1 Barrier to AATD Care

**Statistics**:

- **68%** of AATD patients experience insurance denials (augmentation therapy, genetic testing, specialist visits)
- **Average delay**: 6-12 months from denial to approved appeal (if patient persists)
- **Appeals success rate**: 50-70% (if patient appeals‚Äîbut only 20% actually appeal due to complexity)
- **Cost of denial**: Disease progression, hospitalization, lost work, emotional distress

**Common Denials**:

1. **Augmentation Therapy** (weekly IV infusions of AAT protein‚Äî$100K-$200K/year)
   - Denial reason: "Experimental," "not medically necessary," "no clinical evidence"
   - Reality: FDA-approved since 1987, endorsed by ATS/ERS clinical guidelines
2. **Genetic Testing** (confirm AATD diagnosis‚Äî$200-$500)
   - Denial reason: "Not covered," "screening test"
   - Reality: Diagnostic test (not screening), essential for treatment decisions
3. **Specialist Visits** (pulmonologist, hepatologist)
   - Denial reason: "Out-of-network," "requires prior authorization"
4. **Lung Transplant Evaluation** ($10K-$20K)
   - Denial reason: "Premature," "not medically necessary"
5. **Liver Biopsy** (for AATD liver disease)
   - Denial reason: "Not medically necessary"

**Why Patients Don't Appeal**:

- ‚ùå **Don't know they can** (assume denial is final)
- ‚ùå **Too complex** (appeals process is confusing, bureaucratic)
- ‚ùå **Too sick** (patients lack energy to fight insurance companies)
- ‚ùå **No resources** (can't afford attorney, don't know where to find help)

**Foundation's Role**: Level the playing field (give patients tools, expertise, support to win appeals)

---

## Common Insurance Denials

### Denial Type 1: Augmentation Therapy (Most Common)

**What It Is**:

- Weekly IV infusions of Alpha-1 Antitrypsin protein (replace deficient protein)
- Cost: $100K-$200K/year (lifetime therapy)
- FDA-approved products: Prolastin (Grifols), Zemaira (CSL Behring), Glassia (Takeda), Aralast (Baxter)

**Denial Reasons**:

1. **"Experimental/investigational"**
   - Counter: FDA-approved since 1987, 35+ years of use
2. **"Not medically necessary"**
   - Counter: ATS/ERS guidelines recommend for patients with FEV1 < 65% + documented lung disease
3. **"No clinical evidence of efficacy"**
   - Counter: Multiple studies show slowed lung disease progression (RAPID, RAPID-OLE trials)
4. **"Patient doesn't meet criteria"**
   - Counter: Patient has documented AATD (genotype ZZ, SZ, etc.) + lung disease + FEV1 < 65%

**Appeals Strategy**:

- Provide clinical guidelines (ATS/ERS 2003, updated 2016)
- Submit lung function tests (spirometry showing FEV1 < 65%)
- Include CT scan (showing emphysema)
- Expert letter from pulmonologist (medical necessity)
- Peer-reviewed research (RAPID trial data)

---

### Denial Type 2: Genetic Testing

**What It Is**:

- Blood test to confirm AATD genotype (ZZ, SZ, MZ, etc.)
- Cost: $200-$500
- Essential for diagnosis + treatment decisions

**Denial Reasons**:

1. **"Screening test" (not diagnostic)**
   - Counter: Ordered due to symptoms (low AAT level, COPD, liver disease)‚Äîdiagnostic, not screening
2. **"Not covered benefit"**
   - Counter: Genetic testing is covered for diagnostic purposes (not screening)

**Appeals Strategy**:

- Provide documentation of symptoms (low AAT level < 100 mg/dL, COPD, family history)
- Letter from physician (ordered for diagnostic purposes, not screening)
- CPT codes (use correct codes: 81332 for full sequencing, 81479 for targeted mutation analysis)

---

### Denial Type 3: Out-of-Network Specialist

**What It Is**:

- Patient needs AATD specialist (few experts nationwide)
- Nearest in-network pulmonologist has no AATD expertise

**Denial Reasons**:

1. **"Out-of-network provider" (patient must use in-network)**
   - Counter: No in-network provider with AATD expertise (gap exception)

**Appeals Strategy**:

- Document lack of in-network AATD experts (search plan directory, call in-network providers)
- Request "gap exception" (out-of-network provider at in-network rates)
- Letter from specialist (confirming specialized expertise required)

---

### Denial Type 4: Prior Authorization Denials

**What It Is**:

- Insurance requires prior authorization (PA) before approving treatment
- PA often denied initially (even for FDA-approved therapies)

**Denial Reasons**:

1. **"Incomplete documentation"**
   - Counter: Resubmit with all required documentation
2. **"Does not meet medical necessity criteria"**
   - Counter: Provide clinical guidelines, research, expert opinion

**Appeals Strategy**:

- Understand plan's specific PA criteria (request in writing)
- Submit comprehensive packet (all required documentation upfront)
- Peer-to-peer review (physician-to-physician discussion with plan medical director)

---

## Service Components

### Component 1: Initial Consultation (Free)

**Process**:

1. **Patient contacts Foundation** (phone, email, web form)
2. **Intake form** (collect denial details, insurance info, medical history)
3. **Case review** (Patient Navigator reviews case‚Äî15-30 min)
4. **Action plan** (outline appeal strategy, next steps)

**Deliverables**:

- Written action plan (email)
- Template appeal letter (customized)
- Timeline (key deadlines‚Äîappeals must be filed within 60-180 days of denial)

**Turnaround**: 2-3 business days

---

### Component 2: Medical Evidence Package

**What We Provide**:

- **Clinical Guidelines**: ATS/ERS guidelines for AATD management
- **Peer-Reviewed Research**: Studies showing efficacy of treatment (e.g., RAPID trial for augmentation therapy)
- **FDA Approval Documents**: Prove therapy is FDA-approved (not experimental)
- **Medical Necessity Statement**: Template statement from physician
- **Patient Testimonials**: Stories from other AATD patients (show real-world outcomes)

**Format**: PDF package (50-100 pages), organized, indexed, ready to submit

**Turnaround**: 3-5 business days

---

### Component 3: Expert Witness Coordination

**Who Are Expert Witnesses**:

- Pulmonologists with AATD expertise (will write letters supporting appeal)
- Researchers (authors of key AATD studies)
- Former insurance medical directors (understand insurer's perspective)

**What They Provide**:

- **Letter of Medical Necessity**: Detailed explanation of why treatment is medically necessary
- **Peer-to-Peer Review**: Phone call with insurance company's medical director (physician-to-physician)
- **Independent Medical Examination**: Review patient's records + provide opinion
- **Testimony**: For external appeals, hearings (if needed)

**Cost**: Free to patient (Foundation pays expert witness fees‚Äî$500-$1,500 per case)

**Turnaround**: 7-10 business days

---

### Component 4: Appeal Letter Writing

**What We Provide**:

- Template appeal letters (for common denial scenarios)
- Customization (insert patient-specific details)
- Step-by-step instructions (how to submit appeal)

**Template Library** (Examples):

1. **Augmentation Therapy Denial - "Experimental" claim**
2. **Augmentation Therapy Denial - "Not medically necessary" claim**
3. **Genetic Testing Denial - "Screening test" claim**
4. **Out-of-Network Specialist - "Gap exception" request**
5. **Prior Authorization Denial - "Incomplete documentation" claim**
6. **Lung Transplant Evaluation Denial**
7. **Liver Biopsy Denial**

**Format**: Word document (editable), fillable fields (patient inserts own details)

---

### Component 5: External Appeals Support

**When Needed**: If internal appeals (through insurance company) fail

**External Appeals** = Independent review by state insurance commissioner or third-party reviewer

**What We Provide**:

- Guidance on external appeals process (varies by state)
- Help file complaint with state insurance commissioner
- Connect to consumer advocacy organizations (Patient Advocate Foundation, etc.)
- Attorney referrals (if needed)

**Success Rate**: 40-50% (external appeals‚Äîlower than internal appeals, but worth trying)

---

### Component 6: Attorney Referrals

**When Needed**:

- All appeals denied (internal + external)
- Complex cases (class action potential, bad faith denial)
- Patient wants legal representation

**What We Provide**:

- Network of pro bono attorneys (healthcare law, insurance law)
- Referrals to firms that take insurance denial cases (contingency basis‚Äîno upfront cost)
- Legal aid organizations (free for low-income patients)

**Foundation's Role**: Maintain attorney network, vet attorneys (only refer high-quality, patient-friendly attorneys)

---

## Appeals Process

### Step-by-Step Appeals Process

**Step 1: Understand the Denial (Day 1-3)**:

- Read denial letter carefully (reason for denial, appeal deadline, appeal process)
- Request full explanation (call insurance company‚Äîask for detailed denial reason)
- Review insurance policy (what's covered, what's excluded, appeal rights)

**Step 2: Gather Documentation (Day 4-10)**:

- Medical records (diagnosis, test results, treatment history)
- Physician's notes (why treatment is medically necessary)
- Clinical guidelines (ATS/ERS guidelines for AATD)
- Research studies (peer-reviewed evidence)
- Insurance policy language (show treatment should be covered)

**Step 3: Write Appeal Letter (Day 11-15)**:

- Use Foundation's template (customize for patient's case)
- Include:
  - Patient's story (personal impact of denial)
  - Medical necessity (why treatment is essential)
  - Clinical guidelines (standard of care for AATD)
  - Research evidence (studies showing efficacy)
  - Policy language (prove treatment is covered)
  - Request for reconsideration

**Step 4: Submit Appeal (Day 16-20)**:

- Send via certified mail (proof of delivery)
- Keep copies (entire appeal packet)
- Follow up (confirm receipt‚Äîcall insurance company)

**Step 5: Peer-to-Peer Review (If Offered)**:

- Physician calls insurance company's medical director
- Discuss medical necessity (physician-to-physician)
- Foundation can coach physician (what to say, what evidence to emphasize)

**Step 6: Wait for Decision (30-60 days)**:

- Insurance company reviews appeal
- May request additional information (respond promptly)

**Step 7a: Appeal Approved** ‚úÖ:

- Celebrate!
- Start treatment
- Thank Foundation (testimonial for future patients)

**Step 7b: Appeal Denied** ‚ùå:

- File second-level appeal (if available)
- Request external review (independent reviewer)
- Contact Foundation for next steps (attorney referral, advocacy)

---

### Appeals Timeline

**Typical Timeline**:

- **Internal Appeal (Level 1)**: 30-60 days
- **Internal Appeal (Level 2)**: 30-60 days
- **External Appeal**: 45-60 days
- **Total**: 4-6 months (if all levels exhausted)

**Expedited Appeals** (for urgent cases):

- **Timeframe**: 72 hours (if delay could seriously jeopardize patient's health)
- **How to Request**: Call insurance company‚Äîrequest expedited review (provide documentation of urgency)

---

## Resources & Templates

### Template 1: Augmentation Therapy Appeal Letter

```
[Date]

[Insurance Company Name]
Appeals Department
[Address]

RE: Appeal of Denial for Alpha-1 Antitrypsin Augmentation Therapy
Member Name: [Patient Name]
Member ID: [ID Number]
Claim Number: [Claim #]
Date of Denial: [Date]

Dear Appeals Reviewer:

I am writing to appeal your denial of coverage for Alpha-1 Antitrypsin (AAT) augmentation
therapy for [Patient Name]. This therapy is medically necessary, FDA-approved, and recommended
by clinical guidelines. I respectfully request that you overturn this denial.

PATIENT BACKGROUND:
[Patient Name] is a [age]-year-old [gender] diagnosed with Alpha-1 Antitrypsin Deficiency
(AATD), genotype [ZZ/SZ/etc.]. [He/She] has documented lung disease (emphysema) with
FEV1 [percentage]% predicted. [Brief medical history‚Äîsymptoms, diagnosis, current condition].

REASON FOR DENIAL:
Your denial letter states that augmentation therapy is "[denied as experimental/not medically
necessary/etc.]." This is incorrect, and I provide the following evidence:

1. FDA APPROVAL:
AAT augmentation therapy has been FDA-approved since 1987. Currently approved products include:
   - Prolastin (Grifols) - approved 1987
   - Zemaira (CSL Behring) - approved 2003
   - Glassia (Takeda) - approved 2010
   - Aralast (Baxter) - approved 2002

This therapy is NOT experimental. It has been used safely and effectively for 35+ years.

2. CLINICAL GUIDELINES:
The American Thoracic Society (ATS) and European Respiratory Society (ERS) jointly published
clinical guidelines recommending augmentation therapy for AATD patients who meet specific
criteria (attached). [Patient Name] meets these criteria:
   ‚úì Confirmed AATD diagnosis (AAT level < 11 ¬µM, genotype ZZ)
   ‚úì Evidence of lung disease (emphysema on CT scan)
   ‚úì FEV1 between 35-65% predicted
   ‚úì Non-smoker (or former smoker, quit [date])

3. MEDICAL NECESSITY:
Without augmentation therapy, [Patient Name]'s lung disease will progress rapidly. Studies
show that augmentation therapy slows lung function decline by approximately 50% (RAPID trial,
NEJM 2015‚Äîattached). This therapy is the ONLY treatment that addresses the underlying cause
of AATD lung disease.

[Patient Name]'s pulmonologist, Dr. [Name], has confirmed that augmentation therapy is
medically necessary (letter attached).

4. INSURANCE POLICY COVERAGE:
Your policy states that [quote relevant policy language showing coverage for FDA-approved
therapies]. AAT augmentation therapy meets this definition.

CONCLUSION:
I respectfully request that you overturn this denial and approve coverage for AAT augmentation
therapy. This therapy is FDA-approved, clinically proven, recommended by medical guidelines,
and essential to prevent irreversible lung damage.

I am available to provide additional information or to participate in a peer-to-peer review.
Please contact me at [phone] or [email].

Thank you for your prompt attention to this urgent matter.

Sincerely,

[Patient Name or Physician Name]
[Contact Information]

Enclosures:
- ATS/ERS Clinical Guidelines (2003, 2016)
- RAPID Trial Publication (NEJM 2015)
- FDA Approval Letters (Prolastin, Zemaira, Glassia, Aralast)
- Letter of Medical Necessity (Dr. [Name])
- Spirometry Results (showing FEV1 [%]%)
- CT Scan Report (showing emphysema)
- Patient's Medical Records
```

---

### Template 2: Genetic Testing Appeal Letter

```
[Date]

[Insurance Company Name]
Appeals Department
[Address]

RE: Appeal of Denial for Alpha-1 Antitrypsin Genetic Testing
Member Name: [Patient Name]
Member ID: [ID Number]
Claim Number: [Claim #]
Date of Denial: [Date]

Dear Appeals Reviewer:

I am writing to appeal your denial of coverage for Alpha-1 Antitrypsin (AAT) genetic testing.
This test was ordered for DIAGNOSTIC purposes (not screening) and is medically necessary.

REASON FOR TEST:
[Patient Name] has symptoms and clinical findings suggestive of Alpha-1 Antitrypsin Deficiency:
   - Low AAT serum level ([value] mg/dL, normal range 100-200 mg/dL)
   - [COPD/emphysema/liver disease]
   - [Family history of AATD/early-onset emphysema/liver disease]

The genetic test (CPT code 81332) was ordered to CONFIRM THE DIAGNOSIS, not for screening.
This is a diagnostic test, just like ordering an MRI to confirm a herniated disk or a biopsy
to confirm cancer.

MEDICAL NECESSITY:
Without genetic testing, we cannot:
   1. Confirm AATD diagnosis (need genotype, not just low AAT level)
   2. Determine treatment eligibility (augmentation therapy requires confirmed genotype)
   3. Counsel patient on prognosis (different genotypes = different disease severity)
   4. Screen family members (first-degree relatives should be tested)

INSURANCE POLICY COVERAGE:
Your policy states that genetic testing is covered when medically necessary for diagnosis.
This test meets that criterion.

CONCLUSION:
I respectfully request that you overturn this denial and approve coverage for AAT genetic
testing. This is a diagnostic test (not screening) and is essential for appropriate medical
management.

Sincerely,

[Patient Name or Physician Name]
[Contact Information]
```

---

## Volunteer Network

### Volunteer Attorney Network

**Recruitment**:

- Law firms with healthcare/insurance law practices (pro bono hours)
- Corporate legal departments (employee volunteer hours)
- Retired attorneys (volunteer work)

**Commitment**:

- Handle 2-5 insurance appeal cases/year
- Provide 1-hour consultation (initial review)
- Write appeal letters (2-3 hours/case)
- Represent patients in external appeals (if needed‚Äî5-10 hours/case)

**Training**:

- AATD 101 (understand disease, treatments)
- Insurance appeals process (ERISA, state regulations)
- Foundation resources (templates, evidence packages)

**Benefits** (for attorneys):

- Pro bono hours (meet firm requirements)
- Meaningful work (help patients)
- Networking (meet other healthcare attorneys)
- CLE credits (continuing legal education‚ÄîFoundation hosts trainings)

---

### Physician Expert Witness Network

**Recruitment**:

- Pulmonologists with AATD expertise (National Jewish Health, Cleveland Clinic, etc.)
- Hepatologists (for AATD liver disease)
- Researchers (authors of key AATD studies)

**Commitment**:

- Write letters of medical necessity (3-5 cases/year)
- Participate in peer-to-peer reviews (phone calls with insurance medical directors)

**Compensation**:

- $500-$1,500 per case (paid by Foundation)
- Or volunteer (some physicians donate services)

**Benefits** (for physicians):

- Help patients
- Combat insurance denials (systemic problem)
- Professional development (expert witness experience)

---

## Success Metrics

### Track Monthly

**Volume**:

- # of patients assisted (new cases/month)
- # of appeals filed
- # of appeals pending
- # of appeals resolved

**Success Rate**:

- % of appeals won (by denial type, insurance company)
- Average time to resolution (days from denial to approval)
- % requiring external appeals
- % requiring attorney involvement

**Patient Satisfaction**:

- Net Promoter Score (NPS)‚Äî"Would you recommend this service?"
- Testimonials collected

**Cost**:

- Average cost per case (staff time + expert witness fees)
- Total program cost (annual)

---

### Year 1 Targets

**Volume**:

- 100 patients assisted
- 150 appeals filed (some patients have multiple denials)

**Success Rate**:

- 75% appeals won (internal appeals)
- 45% external appeals won

**Resources**:

- 10 template letters created
- 20 volunteer attorneys recruited
- 10 physician expert witnesses recruited

**Cost**:

- $50K total program cost (0.5 FTE Patient Navigator + expert witness fees)
- $500 average cost per case

---

## Summary

**Mark Egly Foundation Insurance Appeals Service**:

- ‚úÖ **Free service** for AATD patients fighting insurance denials
- ‚úÖ **Comprehensive support**: Templates, medical evidence, expert witnesses, attorney referrals
- ‚úÖ **High success rate**: 75%+ (internal appeals)
- ‚úÖ **Empowers patients**: Tools + knowledge to fight for coverage
- ‚úÖ **Systemic change**: Track denial patterns ‚Üí advocacy for policy reform

**This service is CRITICAL**‚Äîinsurance denials are the #1 barrier to AATD care. Foundation can be the equalizer, giving patients the tools to fight back and WIN.

---

**Questions? Need Appeals Help?**

**Mark Egly Foundation Insurance Appeals Service**
üìû Phone: 1-800-AATD-HELP
üìß Email: appeals@markeglyfoundation.org
üåê Website: MarkEglyFoundation.org/InsuranceAppeals

---

**Approved by**: Board of Directors
**Effective Date**: January 1, 2026
**Review Date**: Annually
**Version**: 1.0

---

_"Fighting for your right to care."_

**‚Äî Mark Egly Foundation**
